Optimizing Antiviral Outcomes Through Clinical Pharmacology (On-Demand)
Outcomes Through Clinical Pharmacology (On-Demand)
Presenter: Jennifer J. Kiser, PharmD, PhD
Release date: June 21, 2022
Expiration date: June 21, 2023
CME Credit Available: 1.25 AMA PRA Category 1 Credits™
Assessment of Needs
Several new antiviral drugs have become available in recent years including therapies for SARS-CoV2 and long-acting agents for HIV prevention and treatment. This webinar will compare and contrast the clinical pharmacology and concentration-effect associations for contemporary antivirals. Modern analytical approaches to define antiviral pharmacokinetic-dynamic relationships will also be discussed.
At the end of this webinar, participants will be able to:
- Define key clinical pharmacology concepts for antiviral drugs
- Compare and contrast the clinical pharmacology and concentration-effect associations for contemporary antivirals
- Describe modern analytical approaches to define pharmacokinetic-dynamic relationships
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
Conflicts of Interest
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies information for the presenter and planners/reviewers are below and in the presentation. All relevant financial relationships with ineligible companies have been mitigated.
Dr Kiser has no relevant financial relationships with ineligible companies to disclose. (Updated 02/25/22)
Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 03/16/22)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 03/16/22)
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Point
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.
How to Claim Credit
- Start the Activity by clicking "START COURSE" located above.
Please note that the "START COURSE" will no longer be visible once you clicked it once.
- Watch the webinar here.
- Return to this page and follow this link to the evaluation form.
- Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
- Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.